January 8, 2026 7:27am

Dramatic C&GT sector share pricing upsides usually come at a price; as “uncle algo and his electronic trading dwarfs” are hungry for profiteering!

Pre-open Signals: 1 Sell into Strength, 2 Negative, many non-pre-open indications; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t!

 

No Don Quixote as I continually ask, what do all these stock sources, I-Banks and brokers do for you in providing daily information? Availability of data have made intel both complex; I see myself as a collector and my responsibility is to further identify and interpret data to bridge some gaps in an investment decision.

Wednesday’s RMi Closing Bell: Bounciness … https://www.regmedinvestors.com/articles/14258

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP! …

https://www.regmedinvestors.com/articles/14249   

 

Let’s not forget; Investors this week are awaiting the Supreme Court’s opinions on the legality of tariffs imposed by Trump expected Friday, which could lead to some potential market volatility.

Thursday: The pre-open Dow futures are DOWN -0.39% or (-194 points), the S&P futures are DOWN -0.24% or (-17 points) and the Nasdaq futures are DOWN -0.34% or (-87 points)

  • U.S. stock futures are falling, Thursday 1/8
  • European markets are fluctuating,
  • Asia Pacific markets mostly fall.

 

Economic Data:  7:30 am - Challenger Job Cuts and at 8:30am - Initial Jobless Claims

  • On Friday, the December jobs report is expected to show a slowdown in hiring in the final month of 2025, with economists expecting nonfarm payrolls to grow by 55,000, down from November's job gains of 64,000. The unemployment rate, which hit a four-year high of 4.6% in November, is expected to fall by 0.1%.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Wednesday: The Dow closed DOWN -466.00 points or -0.94%, the S&P closed DOWN -23.89 points or -0.34% while the Nasdaq closed UP +37.102 points or +0.16%
  • Tuesday: The Dow closed UP +484.90 points or +0.99%, the S&P closed UP +42.67 points or +0.62% while the Nasdaq closed UP +151.351 points or +0.65%
  • Monday: The Dow closed UP +594.79 points or +1.23%, the S&P closed UP +43.58 points or +0.64% while the Nasdaq closed UP +160.193 points or +0.69%
  • Last week: The S&P 500 was down -1.2%, the Dow was down -1.3% and the Nasdaq was down -1.5%.
  • The previous week: The S&P 500 was up +1.4%, the Dow +1% and the Nasdaq was also up +0.1%
  • December ended with the S&P 500 up +16.4%, the Dow +13% and the Nasdaq +20.4%

 

Q1/26 – Q1 – 1 holiday, 1 negative and 3 positive closes  

Q4 – December,

  • 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Vertex (VRTX) closed up +$15.77 with a negative -$3.55 or -0.73% pre-open

Sarepta Therapeutics (SRPT) closed up +$1.11 after Tuesday’s +$1.28 with a negative -$0.22 or -0.94% pre-open

Capricor Therapeutics (CAPR) closed up +$0.18 after Tuesday’s +$1.32 after Monday’s -$3.50, Friday’s -$0.55 (-1.91% to $28.31) pre-open NO indication …

  • As CAPR’s investment bank jumps into protecting its offering pricing – Don’t be SWAYED by their BUYING!!
  • I am STICKING to my CONVICTION that CAPR is overbought and whose valuation is disconnected from fundamentals.
  • Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!
  • CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
  • It has begun; timing will be everything!
  • The higher CAPR rises, the steeper the fall!

 

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

In 2026, investors should focus on whether cell and gene therapy sector equities can sustain momentum through clinical execution, regulatory milestones, commercialization progress, financings and potential strategic transactions; although Q4 and FY25 earnings cycle could slow upsides

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Investors are hoping for continued momentum, as the prospects for a Santa Claus rally... flubbed!

  • After a surprise drop in inflation and lukewarm labor market data left betting on possible 2026 interest-rate cuts

 

January – 2nd week’s session

  • 1/7 – Wednesday closed positive with 33 incliners, 5 decliners and 2 flats
  • 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

January first week:

  • 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
  • 1/1 -Thursday was a holiday, New Years Day

Last week of December, Q4 and FY25

  • Wednesday closed negative with 18 positive, 22 negative and 5 flats
  • Tuesday closed negative with 7 positive, 31 negative and 2 flats
  • Monday closed negative with 12 positive, 24 negative and 4 flats

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in past session:   

  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and IQVIA Holdings (IQV),
  • Tuesday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)
  • Monday: IQVIA Holdings (IQV), BioLife Solutions (BLFS), and Vericel (VCEL)

The worst three (3) in past session:

  • Wednesday: Arrowhead Pharmaceuticals (ARWR), BioLife Solutions (BLFS) and LENZ Therapeutics (LENZ)
  • Tuesday: AxoGen (AXGN), Ultragenyx Pharmaceuticals (RARE) and Entrada Therapeutics (TRDA)
  • Monday: Capricor Therapeutics (CAPR), Vertex (VRTX) and Arrowhead Pharmaceuticals (ARWR)

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.